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Abstract
Background: Musladin-Lueke Syndrome (MLS) is a hereditary disorder affecting Beagle dogs that manifests with extensive
fibrosis of the skin and joints. In this respect, it resembles human stiff skin syndrome and the Tight skin mouse, each of
which is caused by gene defects affecting fibrillin-1, a major component of tissue microfibrils. The objective of this work was
to determine the genetic basis of MLS and the molecular consequence of the identified mutation.
Methodology and Principal Findings: We mapped the locus for MLS by genome-wide association to a 3.05 Mb haplotype
on canine chromosome 9 (CFA9 (50.11–54.26; praw ,10
27)), which was homozygous and identical-by-descent among all
affected dogs, consistent with recessive inheritance of a founder mutation. Sequence analysis of a candidate gene at this
locus, ADAMTSL2, which is responsible for the human TGFb dysregulation syndrome, Geleophysic Dysplasia (GD), uncovered
a mutation in exon 7 (c.660C.T; p.R221C) perfectly associated with MLS (p-value=10
212). Murine ADAMTSL2 containing
the p.R221C mutation formed anomalous disulfide-bonded dimers when transiently expressed in COS-1, HEK293F and CHO
cells, and was present in the medium of these cells at lower levels than wild-type ADAMTSL2 expressed in parallel.
Conclusions/Significance: The genetic basis of MLS is a founder mutation in ADAMTSL2, previously shown to interact with
latent TGF-b binding protein, which binds fibrillin-1. The molecular effect of the founder mutation on ADAMTSL2 is
formation of disulfide-bonded dimers. Although caused by a distinct mutation, and having a milder phenotype than human
GD, MLS nevertheless offers a new animal model for study of GD, and for prospective insights on mechanisms and pathways
of skin fibrosis and joint contractures.
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Introduction
The critical role of extracellular matrix (ECM) in sequestration
and regulated release or activation of growth factors is highly
relevant to common medical problems such as fibrosis. An
excellent example showcasing this role is regulation of TGF-b by
tissue microfibrils, which contain the glycoprotein fibrillin-1 as a
major constituent. The three TGFb isoforms exist as disulfide-
bonded dimers [1]. Their propeptides are processed intracellularly
by furin, but remain associated with the active dimer (the latency-
associated peptide) [1] as the small latent complex (SLC), which in
turn, binds to latent TGFb–binding protein (LTBP)-1, -3, and -4,
to form a large latent complex (LLC) [1,2,3]. The LLC is
sequestered in the ECM through binding of LTBP1 to the ECM
glycoproteins fibrillin-1 and fibronectin [4,5,6,7]. TGFb activity
appears to be regulated primarily at the level of activation in
ECM, which occurs either by a non-proteolytic mechanism
involving integrins and thrombospondin-1, or via proteolysis of the
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12817LLC [1]. Because of the critical role of TGFb in common medical
disorders, even rare genetic disorders that reveal mechanisms of its
regulation are potentially significant.
Fibrillin-1 mutations have clinically diverse consequences, since
they can result in Marfan syndrome (MFS) [8], an acromelic
dysplasia named Weill-Marchesani syndrome (WMS) [9], stiff skin
syndrome (SSS) [10] and isolated ectopia lentis [11]. In MFS,
fibrillin-1 haploinsufficiency is believed to lead to inadequate
retention of the LLC, giving rise to inappropriate TGFb activity in
the lung, heart valves and aortic root [12,13,14,15]. Recently,
domain-specific mutations affecting fibrillin-1 were reported in
SSS, the cardinal manifestation of which is skin fibrosis and
restricted joint movement [10]. Clinical and mechanistic analysis
of this rare disorder demonstrated similarities with scleroderma, a
hardening of skin, which typically occurs in adults as an acquired
disorder [10]. The Tight skin (Tsk) mouse is caused by an in-frame,
partial duplication of Fbn1 [16,17,18]. Thus, there is a strong link
between fibrillin-1 and skin fibrosis.
Another rare disorder in which skin thickening and joint
contractures are characteristic features, is geleophysic dysplasia
(GD), an acromelic dysplasia in which short stature, characteristic
facies, a pleasant temperament, shortening of the distal phalanges,
and tracheal stenosis are also present [19]. GD results from
recessively inherited ADAMTSL2 mutations [20]. The medium of
GD fibroblasts was found to contain high levels of TGFb, and GD
fibroblasts were shown to have evidence of enhanced TGFb
signaling [20]. ADAMTSL2 binds LTBP1 [20], whose domain
structure resembles the fibrillins, although direct association
between ADAMTSL2 and fibrillin-1 has not yet been reported.
The related acromelic dysplasia, WMS, resembles GD, in having
stiff, thick skin, and stiff joints. However, GD is distinctive in
having severe cardiopulmonary involvement, and often leads to
childhood mortality [19,20]. In contrast to GD, patients with
WMS suffer dislocation of the lens because of a defective zonule,
severe glaucoma, and extreme vision impairment not seen in GD
[21]. In addition to dominant FBN1 mutations [9], WMS is caused
by recessively inherited ADAMTS10 mutations [22,23,24]. The
recent discovery of ADAMTS17 and ADAMTSL4 mutations in a
WMS-like syndrome [24] and in recessive isolated ectopia lentis
[25] respectively, further strengthen genetic associations between
fibrillin-1 microfibrils and the ADAMTS superfamily. This
superfamily contains secreted ADAMTS metalloproteases as well
as ADAMTS-like proteins, which are not proteases, but secreted
glycoproteins whose domain structure resembles the C-terminal
ancillary domains of ADAMTS proteases [26]. In addition to
these genetic associations, ADAMTSL6 was recently shown to
bind fibrillin-1 and to accelerate fibrillin biogenesis in vitro, and in
transgenic mice overexpressing this protein [27]. Thus, several
lines of genetic or experimental evidence suggest a functional link
between members of the ADAMTS superfamily and fibrillin-1
microfibrils or fibrillin-1 binding proteins such as LTBP1.
Although many hereditary disorders in man have canine
counterparts, no TGFb dysregulation syndromes have yet been
identified in the dog. One canine syndrome, originally called
‘‘Chinese beagle syndrome’’ in the lay literature, and subsequently
renamed after two noted beagle breeders, Musladin and Lueke, is
characterized by short stature, thick, taut skin, and severely
restricted joint mobility, thus resembling SSS, GD and WMS in
these aspects. Affected dogs also have broad skulls with wide-set
slanted eyes, creased ears, a hopping, ‘‘tip-toe’’ gait, and pleasant
temperaments. MLS was first reported in Beagles in the 1970s,
with an incidence of 2–3% in British and Australian subpopula-
tions. Musladin and Lueke suggested the disorder was a
Mendelian defect segregating with autosomal recessive inheritance
[28]. Here, the genetic and molecular basis of MLS is described.
We identified a missense founder mutation in ADAMTSL2 that
causes MLS, and have found that the mutation results in the
formation of anomalous disulfide-bonded dimers.
Results
Previous descriptions of MLS phenotypes were verified by
interviews with owners and clinical examination of affected dogs.
As puppies, affected dogs failed to thrive, showed stunted growth,
and reportedly suffered ‘‘phantom’’ bouts of pain. The condition
appeared to stabilize by a year of age, though arthritis was a
common sequel. Affected dogs consistently had short outer digits,
reminiscent of the outer phalanx that is characteristic of children
with Down syndrome. Owners also reported a high-pitched bark
and a particularly ‘gregarious’ temperament. Interestingly, a
‘happy’ temperament is also a hallmark of children with GD.
Seizures were noted in several affected dogs.
Clinical assessment of two affected dogs (Text S1) revealed
thick, inelastic skin, and stiffness of the limbs, which could not be
put through a full range of motion, especially at the distal joints
(Figure 1A–C). The stiffness persisted even under a general
anesthetic. Necropsy of an affected MLS puppy did not reveal any
abnormality in organ systems other than thick skin (Figure 1D),
which was adherent to underlying structures, and dense
craniofacial bone with normal dentition. The linea alba of the
ventral abdominal wall, a well-defined fibrous structure, was
roughly five times the normal width. Because MLS has not been
described previously in the veterinary literature, clinical details of
these cases are summarized as supplemental information (Text
S1).
Genetic mapping of MLS
To determine the genetic basis of MLS, we applied a set of 719
microsatellite markers (2.663.9 cM; 2.862.1 Mb) for genome-
wide association using a case-control design (6 cases, 39 controls).
We found two markers on CFA 9 that were significantly associated
with MLS (Praw=10
25; Figure 2A and Table S1). The markers
(0934_RD and 0937) were separated by 1.46 Mb (51.10–52.60
Mb). We applied 23 additional CA-repeat loci from the region
(canFam2; CFA 9; 48.14–54.88) for fine-mapping (Table S2).
Analysis of data generated with an expanded sample set (15
affecteds; 113 unaffecteds) revealed a haplotype (CFA 9; 50.11–
54.26) that was shared homozygous among all affected dogs
(Figure 2B and Table S3). This suggested inheritance of a
founder mutation. Homozygosity was consistent with recessive
inheritance. The perfect association of the haplotype was highly
significant (p,10
216).
A non-synonymous substitution in ADAMTSL2 of affected
dogs
The critical region contained 112 annotated genes (www.
ensembl.org). Two members of the disintegrin and metallopro-
tease with thrombospondin (ADAMTS) gene family (ADAMTS13
and ADAMTSL2) fell within the conserved haplotype. Four
members of the ADAMTS superfamily, ADAMTS10,
ADAMTS17, ADAMTSL2 and ADAMTSL4 have been impli-
cated in connective tissue disorders, including ADAMTSL2, the
cause of GD [20,22,24,25]. We sequenced the putative coding
regions of both candidate genes (Table S4). A single alteration
was found in the putative seventh exon of ADAMTSL2
(Figure 2C), which was homozygous for the non-reference allele
in an affected dog, and heterozygous in an obligate carrier,
consistent with expectations for a causal mutation. This mutation
An ADAMTSL2 Canine Mutation
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12817Figure 1. Phenotypic presentation of MLS in Beagle dogs. (A) Non-affected (left) and affected (right) Beagles matched by age, sex, and variety.
Note short stature of affected dog. (B) Affected dog showing ear crease (arrow) and unusual stiff sitting posture. (C) Same dog as in B showing hyper-
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arginine to a cysteine at codon 221 (R221C), occurred in a highly
conserved stretch of residues, and was computationally predicted
to negatively impact protein structure and function (Figure S1;
SIFT [29]). The mutation was confirmed in the DNA of all
affected dogs in the study (n=30). Several carriers were identified,
and none showed signs of MLS, consistent with a recessive mode
of inheritance.
cDNA from unaffected dog skin obtained by RT-PCR was
sequenced to verify the exon boundaries inferred from compar-
ative alignments with the human and mouse orthologs. The
ADAMTSL2 transcript was assembled from overlapping RT-PCR
products and Rapid Amplification of cDNA Ends (RACE)
analyses (Genbank accession no. GU220770; Table S5). The
results confirmed the mutation (c.660C.T). ADAMTSL2 predict-
ed a reading frame of 952 aa, and a translation product of
,120 kDa. The presence of seven putative N-linked glycosylation
sites suggested a slightly greater molecular weight (,130–
140 kDa) than predicted, similar to that previously reported
experimentally for mouse ADAMTSL2 [30].
Figure 2. MLS is caused by an ADAMTSL2 mutation. (A) Statistical significance scores from genome-wide case-control analysis of microsatellite-
based genotype data are shown. Included are results for loci used in fine-scale mapping of CFA 9 (n=23, depicted in blue). Multiple p-values
estimated by permutation (10
7 iterations) were saturated for statistical significance at 10
27 (red). (B) Fine-mapping revealed a six-marker haplotype
shared homozygous among all affected dogs (Table S2). The haplotype encompassed a strong candidate gene, ADAMTSL2 (depicted in red). (C) DNA
sequence analysis identified the c.660C.T mutation. Sequence traces from PCR products amplified from genomic DNA are shown for a non-affected
(Wt) and affected (Aff) Beagle. The transition (C . T) converts an arginine residue to a cysteine (R221C).
doi:10.1371/journal.pone.0012817.g002
digitigrade standing (arrow), which is also noticeable in panel B. The typical facial appearance is seen in B and C. (D). Histology of skin from an MLS
case compared to skin from an unaffected dog (WT). Stain: Masson trichrome (collagen=blue). Note the increased intensity and extent of blue
staining corresponding to collagen and the presence of collagen strands extending from the dermis to underlying tissue in MLS skin. E, epidermis, D,
dermis, SC, subcutaneous fat.
doi:10.1371/journal.pone.0012817.g001
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function
We tested for a functional effect by introducing the mutation
(c.660C.T) into murine Adamtsl2 cDNA (R221C ADAMTSL2)
and expressing the construct by transient transfection in three cell
lines: HEK293F, COS-1, and CHO-K1 (Figure 3A–C). Condi-
tioned media and cell lysates wereanalyzed by western analysis with
an antibody directed against a C-terminal myc-tag. Under reducing
conditions, the expected ,140 kDa immunoreactive species for
both wild-type and R221C ADAMTSL2 was observed in media
from each cell line. The same experiments were done under non-
reducing conditions to explore the possibility of covalent interac-
tions through the new Cys residue (Figure 3A). These experiments
revealed an R221C ADAMTSL2 protein species of about twice the
molecularweightofwild-typeADAMTSL2(i.e.,280 kDainstead of
140 kDa) in each of the three cell lines. The contrasting results with
reducing and non-reducing analyses implied that the 280 kDa
species represented dimers of R221C ADAMTSL2, arising from
reducible disulfide bridges formed by the mutant cysteine residues.
Low levels of a ,280 kDa species were also detected in conditioned
medium of HEK293F, COS-1 and CHO-K1 cells expressing wild-
type ADAMTSL2, suggesting that there may normally be some
non-covalent self-association of wild-type ADAMTSL2. In condi-
tioned medium, the signal intensity of the mutant protein was
decreased relative to the control transfection in each cell type
(Figure 3B–C). No significant difference was observed in the cell
lysates (Figure 3C).
Discussion
Rare human hereditary disorders such as GD often present
logistical challenges for study, particularly in recruiting sufficient
familial or population cohorts. In contrast, hereditary diseases in
the dog sidestep these obstacles, either because crosses can be
directed to produce an experimental cohort, or more commonly
because inbreeding and favorable pedigree structure (i.e., large
sibships and multiple generations of extant animals) afford
sufficient numbers of affected animals. Another advantage of
canine clinical genetics is that allelic and locus heterogeneity is
seldom confounding in breed-based mapping. Causal mutations
often trace back to a common ancestor within the breed, in many
cases to a single animal of foundation stock. Our data suggest this
was likely the case for MLS in Beagles. Unique breed predilection
suggested the mutation arose within the Beagle gene pool. The
disease has been described in England, Australia, America, and
Japan, implying an allele age that would afford distribution among
broad geographic subpopulations. Accordingly, the mutation
probably originated around the time the modern Beagle was
being developed, possibly at the end of the nineteenth century.
The mutation detection test resulting from this work will assist
Beagle breeders in eliminating the mutation from the gene pool.
Although allele frequency in the breed is not yet known, the Beagle
is one of the more popular breeds with a relatively large
population size for purebred dogs. Accordingly, breed diversity
need not be negatively impacted by marker-assisted selection.
Some breeders may develop a customized strategy to accommo-
date a high incidence of the mutation in their bloodlines to
eradicate the mutation more gradually (e.g. continuing to include
carriers in the breeding stock, but avoiding crosses that would
produce affected offspring).
Comparative aspects of canine MLS and human GD
Our results show that canine MLS is genetically a counterpart
of human GD, a rare disorder whose genetic basis was only
recently resolved [20]. Associated phenotypes common to both
species include short stature, thick skin, joint contractures, and
characteristic facies [19]. A pleasant temperament is reported in
humans with GD as well as in dogs, but it has not been formally
substantiated in the latter [31]. There are, however, several
important features that distinguish the two disorders. In humans,
GD can lead to early death stemming from cardiovascular and
respiratory complications, which can progress relentlessly over the
course of the disease [19]. In contrast, MLS is reported to stabilize
after about a year of age and is not lethal. The differences may be
attributable to allelic differences, or the canine mutation may have
distinct tissue-specific consequences that sidestep cardiovascular
and pulmonary effects. Alternatively, genetic and/or physiological
background differences between the two species may account for
phenotypic variation. Determining the nature of these differences
could suggest therapeutic interventions that ameliorate GD, and
modify the human disorder toward non-fatal MLS.
Variable expression is reported in both GD and MLS, with
much greater variability encountered in GD. The mutations
described to date for GD include both nonsense mutations as well
as subtle missense changes that appear to result in decreased
secretion of ADAMTSL2 [20]. Thus, variable expression of GD
could stem from the very different nature of alleles (ranging from
nullisomic to hypomorphic mutations), occurring furthermore on a
more variable genetic background than in beagles. This is unlikely
to explain variable expressivity in canine MLS—an identical
mutation was found in all affected dogs and the mutation was
characterized on a relatively homogenous breed background.
Molecular consequences of the ADAMTSL2 mutation in
MLS
Previous work showed that mouse ADAMTSL2 mRNA is
expressed by skin and perichondrial fibroblasts, and by vascular
smooth muscle cells in the lung and large vessels [30]. Tissues
containing these cells appeared to be affected which suggests that
the role of ADAMTSL2 is local rather than systemic. Indeed,
following expression in COS-1 cells, it is localized to the
pericellular ECM [30]. The R221C substitution affected
ADAMTSL2 by leading to secretion of disulfide-bonded homo-
dimers of mutant ADAMTSL2. In addition, an overall reduction
of protein level (i.e. following reduction) was also noted. We
speculate that these mutant dimers are non-functional, either in
their binding to LTBP1, or to another ECM or cell-surface
constituent, with consequent loss of a local regulatory role in TGF-
b sequestration or activation. These possibilities will be the subject
of future investigations.
Potential relevance of MLS as an animal model for GD
As an animal model, MLS offers a chance to explore treatments
for human GD. Therapeutic intervention is of limited clinical
value in the dog because eugenics (i.e., DNA-based selective
breeding) has the potential to eliminate the mutation, and thus the
disease. MLS dogs may serve as an in vivo model for evaluating
treatment, since no disease-modifying treatment is currently
available for patients with GD. MLS may also provide a model
to evaluate therapies aimed at reducing TGFb signaling in
acquired fibrotic diseases, such as pulmonary, hepatic or renal
fibrosis, scarring following burns or trauma, and scleroderma. For
instance, the angiotensin II receptor (ATIIR)-antagonist losartan
was shown to be effective in preventing the progressive aortic
dilatation seen in Fbn1-deficient mice that was attributed to
enhanced TGFb signaling [32]. In addition, cells and tissues from
beagles with MLS may help to elucidate the mechanisms and
An ADAMTSL2 Canine Mutation
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12817Figure 3. The R221C mutation leads to aberrant ADAMTSL2 dimerization and reduced protein levels. (A). Wild-type (WT) or R221C
murine ADAMTSL2 was used to transfect HEK293F, COS-1 or CHO-K1 cells (each in triplicate). Conditioned media were run under reducing or non
reducing conditions on 6% SDS-polyacrylamide gels, and were analyzed by Western blot using an anti-myc antibody to detect ADAMTSL2. In each
cell type, both wildtype and mutant ADAMTSL2 migrated under reducing conditions at 140 kDa, corresponding to the monomeric (M) size of
glycosylated ADAMTSL2. The 120 kDa species indicated by a double asterisk in CHO K1 medium, corresponds to an unglycosylated form (confirmed
by peptide N-glycanase F digestion, data not shown). Under non-reducing conditions, wildtype ADAMTSL2 migrated predominantly at 140 kDa,
although two quantitatively minor species .250 kDa were also observed. The 280 kDa band may correspond to a dimer (D). In contrast, R221C
ADAMTSL2 migrated in all 3 cell types exclusively as a 280 kDa dimer (D). (B). HEK293F, COS-1 and CHO K1 cells were transiently transfected as
described above, and conditioned media and cell lysates were run on 7.5% SDS-polyacrylamide gels under reducing conditions. ADAMTSL2 protein
was detected with an anti-myc antibody in both conditioned medium (CM) and cell lysate (CL). In addition, cell lysates were probed with an anti-
GAPDH antibody to control for variations in cell numbers. The western blots shown are representative of at least three independent experiments for
each cell type. Note that in conditioned media, the level of R221C ADAMTSL2 was reduced compared to wild type ADAMTSL2, whereas the levels in
cell lysates were not affected. (C). ECL signal following anti-myc immunoblotting of conditioned media and cell lysates were quantified by
densitometry. ADAMTSL2 signal in both conditioned medium and cell lysate was normalized to the GAPDH signal. In conditioned media, the level of
mutant protein was significantly reduced, whereas no significant difference was observed in the cell lysates (Student t-test).
doi:10.1371/journal.pone.0012817.g003
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fibrosis.
Methods
Ethics Statement
The work was conducted with approval of the Animal Care and
Use Committee of University of California-Davis (Protocol
number #12682).
DNA and markers
Samples from affected and non-affected dogs were recruited
through an informal network of private breeders and owners, and
through project announcements in breed newsletters and maga-
zines. Ascertainment was of unknown bias, precluding formal
analyses of inheritance and heritability. DNA was prepared from
blood [33] or buccal swab samples [34] using standard methods.
Affected status was established by gross presentation (i.e., abnormal
gait, joint rigidity, and taut skin). A previously described marker set
wasusedtoscanthegenomeforassociation[Wongetal,2008].The
set comprised 719 loci, with an average spacing of ,5 cM. For fine-
resolution mapping, microsatellites were obtained from DOGSET
[35]. M13-sequence tags were appended to the 59 end of each
forward primer to allow fluorescent label to be incorporated during
PCR [36]. A leader sequence (GTTTCTT) was appended to the 59
end of each reverse primer to catalyze the non-templated enzymatic
addition of a nucleotide to the 39 end of the labeled product strand
[37]. Markers were assembled into sets of six loci suitable for
multiplex PCR. Fine-mapping markers are listed in Table S2.
Genotyping
Microsatellite markers were genotyped using previously de-
scribed methods (Wong et al, submitted). Fluorescently-labeled
PCR products generated from marker-based primer pairs were
analyzed using ABI 3730 capillary instruments. The command
line option in GeneMapper4.0 was used to pre-process files remotely.
Genotypes were scored with standardized (non-relative) allele
assignments consistent across families and populations. All
genotypes were manually curated.
Statistical analyses and computational biology
The software package Mendel [38] was used for association
mapping. Genotypes of individual markers were tested for
differential allele frequency among case and control sample sets.
Statistical significance was established by permutation of ‘case’ and
‘control’ labels (10 million iterations). SIFT was used to assess the
likelihood of a functional effect of the mutation [29].
Mutation detection
Exons were re-sequenced for polymorphisms with primers
obtained from DOGSET [35]. T3 and T7 ‘sequence tags’ were
appended to the 59 ends of each forward and reverse primer,
respectively, to facilitate high-throughput sequencing. Both strands
of each PCR product were sequenced using BigDye Terminator
v3.1 (Applied Biosystems) and cycle sequencing. Phred [39]was
used to assess sequence data quality and ClustalW [40] was used to
align multiple sequences and identify polymorphisms. Sequence
electropherograms were also manually searched for indel poly-
morphisms.
cDNA, RT-PCR, and RACE
For transcript analysis, total RNA was isolated from skin biopsy
of a male rat terrier with an RNeasy Mini Kit (Qiagen). First-
strand cDNA synthesis was performed with Superscript II Reverse
Transcriptase (Invitrogen). RT-PCR was performed with primers
spanning putative exon boundaries (Supplemental Table S5).
RACE was performed with a Marathon Kit (Clontech). PCR
products were cloned with a TOPO TA Cloning Kit (Invitrogen).
Inserts were amplified by colony PCR of transformants using
vector-specific primers (p-topo2.1). Products were sequenced with
T3 and T7 primers.
Cloning, expression, and Western blot analysis
Cloning of murine ADAMTSL2 into the mammalian expres-
sion vector pcDNA3.1(2)/myc-his A (Invitrogen) was described
previously [30]. The R221C mutation was introduced in this
plasmid by site-directed mutagenesis (QuikChange Kit, Strata-
gene, Thousand Oaks, CA). For transient expression, HEK293F,
COS-1 and CHO K1 cells (American Type Culture Collection,
Manassas, VA) were seeded in 6 well plates and grown to 80%
confluency in DMEM (HEK293F, COS) or MEM-a (CHO-K1)
with 10% FBS and antibiotics (100 U/ml penicillin, 100 mg/ml
streptomycin). Cells were transfected overnight with 1 mg plasmid/
6 ml Fugene 6 (Roche Applied Science, Indianapolis, IN). The
next day, the medium was changed from 10% FBS to 1% FBS-
containing fresh medium (1 ml/well). After 48 h, conditioned
media and cells were collected. Cells were lysed in 100 ml Tris-
buffered saline (TBS), 1% Triton X-100 1x EDTA-free complete
protease inhibitor cocktail (Roche). Conditioned media (30–50 ml)
or the cell lysate were run on a 6% or 7.5% SDS-PAGE under
reducing or non-reducing conditions (+/2b-mercaptoethanol).
Western blot was performed using a mouse monoclonal anti-myc
antibody (9E10, Hybridoma Core, Lerner Research Institute,
Cleveland Clinic) at 1:3000 dilution. A secondary antibody
(Jackson Immunoresearch, West Grove, PA) conjugated with
horseradish peroxidase was used at 1:10000. To control for
protein loading, western blot of the cell lysate was done using a
mouse anti-GAPDH antibody (MAB374, Millipore, Billerica,
MA). Blots were analyzed by chemiluminescence using either
the ECL Kit (GE Life sciences, Piscataway, NJ) or the Hyglo Kit
(Denville Scientific Inc., Metuchen, NJ). For densitometry, the
integrated density of bands (pixel x area) was determined with
Image J as described in http://lukemiller.org/journal/2007/08/
quantifying-western-blots-without.html.
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